Genentech


Since 1994, MCS has been the agency of record for Genentech's lytics franchise, including Activase or t-PA, the first FDA-approved treatment for acute ischemic stroke within three hours of symptom onset; and TNKase, a single-bolus thrombolytic for the treatment of heart attack.

Genentech is a leading biotechnology company that discovers, develops, manufactures, and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies.

For more information on Genentech, Inc., please visit the company's web site at www.gene.com.

Qforma


MCS provides corporate communication support for Qforma.

Qforma is an advanced analytics and predictive modeling company specializing in solutions for the pharmaceutical, biotech, and financial services industries. Its customized software applications utilize complex data flows to identify predictive patterns, quantify impacts and alert sales and marketing teams to evolving behaviors that affect product performance. Qforma is headquartered in Santa Fe, NM, with offices in Boston, MA and Princeton, NJ.

For more information on Qforma, please visit the company's web site www.qforma.com.

Reckitt Benckiser


MCS provides public relations expertise to Reckitt Benckiser, formerly Adams Respiratory Therapeutics, in the launching of their first prescription cough and cold product, as well as corporate communication and crisis management support.

Reckitt Benckiser is a specialty pharmaceutical company focused on late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.

For more information on Reckitt Benckiser, please visit the company's web site www.reckittbenckiser.com.

Merck


MCS provides U.S. and international communication support for a variety of products in the thrombosis and immunology franchises. They include: INTEGRILIN®, a GP IIb/IIIa inhibitor for acute coronary syndrome; vorapaxar, an investigational PAR-1 inhibitor for acute coronary syndrome; acadesine, an investigational adenosine-regulating agent for ischemia reperfusion injury; REMICADE®, an anti-TNF therapy for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease, ulcerative colitis and psoriasis; and SIMPONI®, an anti-TNF therapy for rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Merck is the second-largest pharmaceutical company in the world and develops medicines, vaccines, biologic therapies, and consumer and animal products, with operations in more than 140 countries.

For more information on Merck, please visit the company's web site at www.merck.com.

Sciele


MCS provides public relations support to Sciele for the company's product Ulesfia, a unique prescription medication for treating head lice.

Sciele Pharma, Inc. is a pharmaceutical company specializing in sales, marketing and development of branded prescription products focused on Cardiovascular, Diabetes, Women's Health and Pediatrics.

For more information on Sciele, please visit the company's web site at www.sciele.com.

CSL Behring


MCS provides communication support to CSL Behring for Humate-P for the treatment of von Willebrand disease and C1-inhibitor concentrate, an investigational treatment for hereditary angioedema.

CSL Behring is a global leader in the plasma protein biotherapeutics industry. Dedicated to improving the quality of life for patients throughout the world, CSL Behring provides safe and effective plasma-derived and recombinant products and offers patients a wide range of related services. The company's broad portfolio of life-saving therapeutics is used in the treatment of individuals with hemophilia and other bleeding disorders, immune deficiency disorders, and inherited emphysema; for the prevention of hemolytic diseases for the newborn; in cardiac surgery patients; and in shock and burn victims.

For more information on CSL Behring, please visit the company's web site at www.cslbehring.com.

MannKind Corporation


MCS provides communication support to MannKind for its investigational diabetes treatment, AFREZZA. MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its pipeline includes AFREZZA, which has completed phase 3 clinical trials, and MKC253, which is currently in phase 1 clinical trials. Both of these investigational products are being evaluated for their safety and efficacy in the treatment of diabetes.

Head and Neck Cancer Alliance


For the past seven years, MCS has publicized the Head and Neck Cancer Alliance's annual Oral Head and Neck Cancer Awareness Week (OHANCAW) in April, which is designed to increase public awareness of head and neck cancer and encourage at-risk individuals to participate in nationwide free screenings for this life-threatening disease. The mission of the Head and Neck Cancer Alliance is to provide support to head and neck cancer patients throughout the year; educate children and adults about the disease process, treatment, and prevention of head and neck cancer; and support ongoing research in head and neck oncology. For more information please visit the following web sites: www.ohancaw.com or www.headandneck.org.

SCERENE HEALTHCARE


MCS provides corporate and product public relations support to Scerene Healthcare, Inc., an over-the-counter startup company in Peapack, NJ that is dedicated to developing a brand family called Puristics. Utilizing pure ingredients and proprietary technologies, the Puristics brand family will initially include three OTC consumer product lines with plans for further expansion in the years to come. For more information about Scerene, please visit www.scerenehealthcare.com